Newton Biocapital
Venture Capital
Active
Brussels, Belgium
19
8M
13
3.17
4
0.32
2
- Stages of investment
- Areas of investment
Summary
In 2017 was created Newton Biocapital, which is appeared as VC. The main office of represented VC is situated in the Brussels. The fund was located in Europe if to be more exact in Belgium.
The current fund was established by Alain Parthoens. The overall number of key employees were 7.
This Newton Biocapital works on 12 percentage points less the average amount of lead investments comparing to the other organizations. The important activity for fund was in 2018. Considering the real fund results, this VC is 30 percentage points more often commits exit comparing to other organizations. The fund is constantly included in 2-6 investment rounds annually. The top amount of exits for fund were in 2019. The common things for fund are deals in the range of 10 - 50 millions dollars.
Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - Belgium. Among the various public portfolio startups of the fund, we may underline DIM3, Synergia Medical, ChromaCure The fund has no specific favorite in a number of founders of portfolio startups. Among the most popular fund investment industries, there are Project Management, Manufacturing.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Newton Biocapital, startups are often financed by VI Partners AG, Neomed Management, Entrepreneurs Fund. The meaningful sponsors for the fund in investment in the same round are S.R.I.W., SFPI-FPIM, CapDecisif. In the next rounds fund is usually obtained by Go Capital, CapDecisif, Anaxago.
Investor highlights
- Industry focus
- Stage focus
- Geo focus
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 19
- Lead investments
- 4
- Exits
- 2
- Rounds per year
- 3.17
- Follow on index
- 0.32
- Investments by industry
- Biotechnology (15)
- Medical (7)
- Medical Device (5)
- Health Care (5)
- Pharmaceutical (5) Show 5 more
- Investments by region
-
- Belgium (7)
- France (5)
- Japan (6)
- Switzerland (1)
- Peak activity year
- 2018
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 8
- Group Appearance index
- 0.84
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| AbolerIS Pharma | 19 Sep 2023 | Biotechnology | Early Stage Venture | 32M | Pays de la Loire, Nantes, France |
| Acticor Biotech | 06 Nov 2019 | Biotechnology, Pharmaceutical, Therapeutics, Biopharma | Early Stage Venture | 8M | Ile-de-France, Paris, France |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.